Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Véronique Dièras(Centre Eugène Marquis), Hyo S. Han(Moffitt Cancer Center), Bella Kaufman(Sheba Medical Center), Hans Wildiers(KU Leuven), Michael Friedländer(Prince of Wales Hospital), Jean-Pierre Ayoub(Centre Hospitalier de l’Université de Montréal), Shannon L. Puhalla, Igor Bondarenko(Dnipropetrovsk State Medical Academy), Mario Campone(Institut de Cancérologie de l'Ouest), Erik Jakobsen(Vejle Sygehus), Mathilde Jalving(University Medical Center Groningen), Cristina Oprean(West University of Timişoara), Markéta Palácová(Masaryk Memorial Cancer Institute), Yeon Hee Park(Samsung Medical Center), Yaroslav Shparyk, Eduardo Yáñez(Universidad de La Frontera), Nikhil Khandelwal(AbbVie (United States)), Madan G. Kundu(AbbVie (United States)), Matthew W. Dudley(AbbVie (United States)), Christine K. Ratajczak(AbbVie (United States)), David Maag(AbbVie (United States)), Banu Arun(The University of Texas MD Anderson Cancer Center)
The Lancet Oncology
August 27, 2020
Cited by 320Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis